Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Invivyd

Request full access

Developing best-in-class antibodies that can broadly neutralize SARS-CoV-2, SARS-CoV-1 and additional potentially emergent coronaviruses

Waltham, United StatesFounded 2020Biotech & Life Sciences

About Invivyd

Adagio Therapeutics, operating under the brand name Invivyd, is a biotechnology startup focused on the development and delivery of antibody-based therapies to combat viral threats. The company's primary target market includes individuals with weakened immune systems who may not receive adequate protection from traditional vaccinations, such as those who are immunocompromised.

Invivyd's business model revolves around leveraging advanced technologies like viral surveillance, predictive modeling, and antibody engineering to continuously discover and optimize monoclonal antibody candidates. These candidates are designed to protect vulnerable populations from serious viral threats, starting with COVID-19 and potentially expanding to influenza and other high-need indications.

The company's lead candidate, VYD222, is currently in development for the prevention of symptomatic COVID-19 in vulnerable populations, including solid organ and stem cell transplant recipients and individuals with blood cancers.

Invivyd's revenue generation strategy is likely based on the successful development, approval, and commercialization of its antibody therapies. The company may also generate income through strategic partnerships, licensing agreements, and government grants or contracts.

In summary, Invivyd is a forward-thinking biotech startup with a mission to protect the most vulnerable from evolving viral threats through the development of innovative antibody-based therapies.

Source: Dealroom company data

At a glance

Status
Listed
Listing
IPO 2021

Invivyd in the Waltham ecosystem

Live from Dealroom

The Invivyd office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

15 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A5 investors entered at this stage

Series B and later10 investors entered at this stage

Team profiled 3 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Patents

Estimated portfolio value
$2M

5 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

See Invivyd on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.